Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy. Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients. Results: Median time from blood collection to plasma separation was 50 min (20–120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min–5 days) and median turnaround time was 24 h (6 h–5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).
Liquid biopsy is currently approved for management of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. However, one unanswered question is whether the rate of cell-free DNA (cfDNA)-negative samples is due to technical limitations rather than to tumor genetic characteristics. Using four microsatellite markers that map specific chromosomal loci often lost in lung cancer, we conducted a pilot study to investigate whether other alterations, such as loss of heterozygosity (LOH), could be detected in EGFR-negative cfDNA. We analyzed EGFR-mutated NSCLC patients (n = 24) who were positive or negative for EGFR mutations in cfDNA and compared the results with a second cohort of 24 patients bearing KRAS-mutated cancer, which served as a representative control population not exposed to targeted therapy. The results showed that in EGFR-negative post-tyrosine-kinase-inhibitor (TKI) cfDNAs, LOH frequency was significantly higher than in both pre- and post-TKI EGFR-positive cfDNAs. By contrast, no association between KRAS status in cfDNA and number of LOH events was found. In conclusion, our study indicates the feasibility of detecting LOH events in cfDNA from advanced NSCLC and suggests LOH analysis as a new candidate molecular assay to integrate mutation-specific assays.
Background: Extensive-stage small cell lung cancer (ES-SCLC) carries a poor prognosis, with fewer than 7% of patients surviving for five years. While immune checkpoint inhibitors (ICIs) combined with platinum–etoposide have reshaped first-line treatment, no head-to-head trials exist comparing available regimens, leaving the optimal therapeutic choice undefined. Methods: A systematic literature search identified phase III randomized controlled trials (RCTs) evaluating first-line ICI-based regimens in ES-SCLC. Individual patient data (IPD) were reconstructed from Kaplan–Meier curves using the IPDfromKM algorithm. Indirect treatment comparisons were performed using Cox proportional hazards models, with chemotherapy alone as the common comparator. The indirect comparison of tiragolumab efficacy was unanchored due to the design of the SKYSCRAPER-02 study. Restricted mean survival time (RMST), truncated at 27 months, was calculated as an additional measure of treatment effect. Results: Six RCTs were included. All ICI-based regimens improved overall survival (OS) compared to chemotherapy alone, except ipilimumab (HR 0.97, 95% CI 0.86–1.09). Serplulimab demonstrated the most favorable OS benefit (HR 0.55, 95% CI 0.48–0.64; RMST 16.73 months), representing a gain of approximately 4 months over chemotherapy alone and 1.8–2.3 months over atezolizumab and durvalumab. The addition of tiragolumab to atezolizumab plus chemotherapy yielded no significant advantage over atezolizumab alone. Conclusions: This IPD-based indirect comparison suggests that serplulimab plus chemotherapy may offer the most favorable OS estimates S benefit among first-line ICI regimens for ES-SCLC, while durvalumab and atezolizumab remain effective standards of care. These findings are hypothesis-generating and highlight the need for prospective head-to-head comparative studies.